# OnCo record olaparib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/olaparib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "olaparib" ;
  schema:name "Olaparib"@en ;
  schema:description "Olaparib was the first PARP inhibitor, and turned an inherited BRCA mutation from a risk factor into a drug target, including after surgery in breast cancer."@en ;
  schema:url <https://onco.cc/drugs/olaparib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Olaparib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7083106> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Olaparib>, <https://www.nice.org.uk/guidance/ta886>, <https://www.nice.org.uk/guidance/ta1040>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22LYNPARZA%22>, <https://doi.org/10.1200/JCO.21.01604>, <https://www.nice.org.uk/guidance/ta887>, <https://www.nice.org.uk/guidance/ta951> ;
  onco:status "approved" ;
  onco:modality "Small-molecule PARP inhibitor" ;
  schema:alternateName "Lynparza" ;
  onco:approval "US 2014: gBRCA ovarian cancer ≥3 lines", "US 2018: gBRCA HER2- metastatic breast cancer", "US 2022: Adjuvant gBRCA high-risk HER2- early breast cancer", "EU 2019: Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane (OlympiAD)", "EU 2022: Adjuvant treatment, alone or with endocrine therapy, of germline BRCA1/2-mutated HER2-negative high-risk early breast cancer after neoadjuvant or adjuvant chemotherapy (OlympiA)", "UK 2023: Adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy; NICE TA886 (10 May 2023) recommends within the marketing authorisation with a commercial arrangement", "UK 2025: BRCA mutation-positive HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane; NICE TA1040 (12 February 2025) recommends with a commercial arrangement, the lowest-cost option to be used where talazoparib is also suitable", "US 2019: Maintenance treatment of deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of first-line platinum-based chemotherapy (POLO), with an FDA-approved companion diagnostic", "EU 2020: Maintenance treatment of germline BRCA1/2-mutated metastatic pancreatic adenocarcinoma that has not progressed after at least 16 weeks of platinum-based first-line chemotherapy; listed in the EMA Lynparza product information read on 24 September 2026 (extension of indication in 2020)" ;
  onco:acceleratedApproval "US 2014-12-19: Deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer after treatment with 3 or more lines of chemotherapy 2" ;
  onco:acceleratedApprovalConfirmed "US 2017-08-17: Deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer after treatment with 3 or more lines of chemotherapy 2" ;
  onco:related <https://onco.cc/biomarkers/brca-germline/>, <https://onco.cc/biomarkers/brca-somatic/>, <https://onco.cc/biomarkers/hrd-positive/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/tnbc-early/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/>, <https://onco.cc/cancers/brca-palb2-pdac/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/parp/>, <https://onco.cc/targets/brca/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/prostate-hrr-eligibility/>, <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/olympia/>, <https://onco.cc/trials/nct04884360/>, <https://onco.cc/trials/nct04421963/>, <https://onco.cc/trials/nct04624204/>, <https://onco.cc/trials/nct05171816/>, <https://onco.cc/trials/nct06915025/>, <https://onco.cc/trials/nct01081951/>, <https://onco.cc/trials/nct06686030/>, <https://onco.cc/trials/nct07024784/>, <https://onco.cc/trials/nct04644289/>, <https://onco.cc/trials/nct03775486/>, <https://onco.cc/trials/nct02861573/>, <https://onco.cc/trials/nct06909825/>, <https://onco.cc/trials/nct05898399/>, <https://onco.cc/trials/nct06525298/>, <https://onco.cc/trials/nct05498155/>, <https://onco.cc/trials/nct01874353/>, <https://onco.cc/trials/nct02734004/>, <https://onco.cc/trials/nct03742895/>, <https://onco.cc/trials/nct06353386/>, <https://onco.cc/trials/nct03459846/>, <https://onco.cc/trials/nct04380636/>, <https://onco.cc/trials/partner/>, <https://onco.cc/trials/phoenix/>, <https://onco.cc/trials/nct06112379/>, <https://onco.cc/trials/polo/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-olympia-nejm-2021/>, <https://onco.cc/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/>, <https://onco.cc/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/>, <https://onco.cc/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/>, <https://onco.cc/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/>, <https://onco.cc/key-papers/paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018/> .